

MSF Access Campaign sent an open letter to pharmaceutical corporation AbbVie, urging them to make the medicine glecaprevir/pibrentasvir (G/P) more accessible to treat people with hepatitis C in low- and middle-income countries (LMICs), including in MSF programmes.
Since 2018, MSF has made numerous requests to AbbVie to enable the procurement of G/P. But this lifesaving treatment continues to remain out of reach for many people with hepatitis C in LMICs.
MSF calls on AbbVie to: